Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Status:
Not yet recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for
concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose
of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus
hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary
endpoint along with progression-free survival, toxicity, quality of life, and prognostic
biomarkers.